SPTX Stock Forecast & Price Target

Seaport Therapeutics is attractive because it targets large, underpenetrated neuropsychiatric markets, including anxiety disorders affecting more than 300M people worldwide, while advancing clinically validated mechanisms that have been constrained by poor bioavailability and tolerability. Its Glyph platform has already shown strong de-risking data, including a 6.8-fold increase in agomelatine bioavailability versus unmodified drug, no serious or severe adverse events, and no clinically significant liver-related lab changes, while GlyphAllo’s driving study showed no next-morning impairment at 375mg or 250mg and was well tolerated. With BUOY-1 top-line data slated for 1H27, additional GlyphAgo data in early 2028 and year-end 2028, and a differentiated non-hallucinogenic pipeline that could reduce monitoring burden and improve convenience, the company has multiple catalysts supporting long-term upside.

Seaport Therapeutics is a clinical-stage company whose value depends heavily on GlyphAllo and GlyphAgo, yet both assets remain unproven and exposed to the binary risk of negative clinical results, failure to complete development, or lack of regulatory approval in major territories. Even with ~$427M in cash, cash equivalents and marketable securities as of mid-2026, the DCF relies on only 60% approval probability for GlyphAllo and 40% for GlyphAgo, highlighting substantial execution uncertainty and a heavy dependence on markets for depression and anxiety that may not convert into commercial success. Its long patent life and ~$2.74B enterprise value do not offset risks from lower-than-expected sales uptake, partnership dependence, drug pricing and market access pressures, and possible long-term equity dilution, all of which support a negative fundamental outlook.